지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
이용수4
국문요약 ················································································································ⅠList of Figures ·································································································· ⅢList of Tables ···································································································· ⅣⅠ. 서 론 ········································································································ 1Ⅱ. 실험재료 및 실험방법 ················································································ 121. 실험재료 ····································································································· 122. β-hexosaminidase 측정 ········································································ 143. RT-PCR(Reverse Transcriptase-Polymerase Chain Reaction) ········ 154. Immunoblot analysis ·············································································· 165. Passive cutaneous anaphylaxis(PCA) ············································· 176. Histological analysis ············································································· 187. 통계학적 분석 ····························································································· 18Ⅲ. 실험 결과 ······································································································ 191. CPE의 항원자극으로 유발된 비만세포 탈과립의 억제 효과 ········· 192. CPE 처리 시 RBL-2H3세포에서 항원에 의해 유도된 TNF-α, IL-4expression 억제 효과 ······················································································ 223. CPE의 ionomycin과 thapsigargin으로 유도된 RBL-2H3세포의 탈과립에 대한 억제 효과 ······················································································· 244. CPE 처리 시 RBL-2H3 cells과 BMMCs에서의 Syk 및 하위 신호전달 단백질들의 인산화 억제 효과 ································································· 265. In vivo 상에서의 CPE의 알레르기 억제 효과 ·································· 28Ⅳ. 고 찰 ······································································································ 30Ⅴ. 참고 문헌 ······································································································ 33Abstract ··············································································································· 40
0